Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyadic International Inc. stock logo
DYAI
Dyadic International
$1.05
+5.5%		$0.96
$0.65
▼
$1.60
$38.26M1.12179,861 shs203,622 shs
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
$30.00
+5.0%		$0.00
$7.21
▼
$37.90
$40.20M-0.25204,728 shs217,442 shs
Immuron stock logo
IMRN
Immuron
$1.10
$1.15
$0.68
▼
$2.39
$8.88M1.15122,498 shs14,664 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$2.86
+2.1%		$4.03
$2.62
▼
$16.25
$37.47M1.63102,730 shs29,460 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyadic International Inc. stock logo
DYAI
Dyadic International
-0.48%-6.11%-6.11%+37.69%+6.21%
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
+17.14%+4.50%-20.99%+2,856,999,900.00%+2,856,999,900.00%
Immuron stock logo
IMRN
Immuron
+3.29%+3.77%-10.57%+37.33%-34.33%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
0.00%-9.97%-35.93%-32.69%-40.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyadic International Inc. stock logo
DYAI
Dyadic International
$1.05
+5.5%		$0.96
$0.65
▼
$1.60
$38.26M1.12179,861 shs203,622 shs
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
$30.00
+5.0%		$0.00
$7.21
▼
$37.90
$40.20M-0.25204,728 shs217,442 shs
Immuron stock logo
IMRN
Immuron
$1.10
$1.15
$0.68
▼
$2.39
$8.88M1.15122,498 shs14,664 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$2.86
+2.1%		$4.03
$2.62
▼
$16.25
$37.47M1.63102,730 shs29,460 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyadic International Inc. stock logo
DYAI
Dyadic International
-0.48%-6.11%-6.11%+37.69%+6.21%
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
+17.14%+4.50%-20.99%+2,856,999,900.00%+2,856,999,900.00%
Immuron stock logo
IMRN
Immuron
+3.29%+3.77%-10.57%+37.33%-34.33%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
0.00%-9.97%-35.93%-32.69%-40.17%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dyadic International Inc. stock logo
DYAI
Dyadic International
2.33
Hold$3.00185.71% Upside
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
2.83
Moderate Buy$54.9083.00% Upside
Immuron stock logo
IMRN
Immuron
1.00
SellN/AN/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
2.33
Hold$11.00284.62% Upside

Current Analyst Ratings Breakdown

Latest IMRN, DYAI, FTH, and RADX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$60.00
8/4/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
JonesTrading logo
JonesTrading
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$55.00
7/31/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$56.00
7/28/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$60.00
7/20/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$51.00
7/17/2026
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/16/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$55.00
6/26/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$57.00
6/25/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/24/2026
Dyadic International Inc. stock logo
DYAI
Dyadic International
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Immuron stock logo
IMRN
Immuron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dyadic International Inc. stock logo
DYAI
Dyadic International
$3.09M12.38N/AN/A$0.03 per share35.00
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
N/AN/AN/AN/A$14.74 per shareN/A
Immuron stock logo
IMRN
Immuron
$4.72M1.88N/AN/A$0.78 per share1.41
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$2.35M15.94N/AN/A$3.52 per share0.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dyadic International Inc. stock logo
DYAI
Dyadic International
-$7.36M-$0.23N/AN/AN/A-192.40%-1,005.45%-77.64%8/12/2026 (Estimated)
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
-$21.08M-$141.65N/AN/AN/AN/A-1,012.17%-175.69%N/A
Immuron stock logo
IMRN
Immuron
-$3.38MN/AN/AN/AN/AN/AN/AN/A8/28/2026 (Estimated)
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
-$24.83MN/AN/AN/AN/AN/AN/AN/AN/A

Latest IMRN, DYAI, FTH, and RADX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/28/2026N/A
Immuron stock logo
IMRN
Immuron
-$0.0037N/AN/AN/A$2.75 millionN/A
8/12/2026Q2 2026
Dyadic International Inc. stock logo
DYAI
Dyadic International
-$0.03N/AN/AN/A$1.03 millionN/A
5/15/2026Q1 2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
N/A-$131.45N/A-$131.45N/AN/A
5/15/2026Q4 2025
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
-$0.62-$131.45-$130.83-$131.45N/AN/A
5/13/2026Q1 2026
Dyadic International Inc. stock logo
DYAI
Dyadic International
-$0.04-$0.05-$0.01-$0.05$0.90 million$1.11 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Dyadic International Inc. stock logo
DYAI
Dyadic International
N/AN/AN/AN/AN/A
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
N/AN/AN/AN/AN/A
Immuron stock logo
IMRN
Immuron
N/AN/AN/AN/AN/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dyadic International Inc. stock logo
DYAI
Dyadic International
4.08
2.42
2.42
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
N/A
19.69
19.69
Immuron stock logo
IMRN
Immuron
N/A
8.04
6.83
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
3.01
N/A

Institutional Ownership

CompanyInstitutional Ownership
Dyadic International Inc. stock logo
DYAI
Dyadic International
27.95%
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
10.50%
Immuron stock logo
IMRN
Immuron
0.12%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A

Insider Ownership

CompanyInsider Ownership
Dyadic International Inc. stock logo
DYAI
Dyadic International
20.90%
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
7.00%
Immuron stock logo
IMRN
Immuron
7.01%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Dyadic International Inc. stock logo
DYAI
Dyadic International
736.44 million28.82 millionOptionable
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
401.34 million1.25 millionNot Optionable
Immuron stock logo
IMRN
Immuron
N/A8.07 million7.51 millionNot Optionable
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A13.10 millionN/AN/A

Recent News About These Companies

RADX: RAD101 Topline & FY:26 Cash Flows
August 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/radx-rad101-topline-fy-26-151400375.html
RADX FY2026 EPS Estimate Cut by Brookline Capital Markets
August 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30933513
Radiopharm Dips on Securities Pact
July 25, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23725/Radiopharm-Dips-on-Securities-Pact
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
July 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/24/3332785/0/en/radiopharm-theranostics-announces-concurrent-us-4-1-million-registered-direct-offering-and-up-to-additional-a-12-7-us-8-9-million-australian-placement-and-share-purchase-plan.html
Radiopharm Highlights Data Release
July 23, 2026  |  baystreet.cahttps://www.baystreet.ca/techinsider/5668/Radiopharm-Highlights-Data-Release
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331243/0/en/radiopharm-theranostics-achieves-confirmed-durable-partial-response-in-ongoing-phase-1-trial-of-rad204-in-patients-with-advanced-solid-tumors-post-immunotherapy.html
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331214/0/en/radiopharm-theranostics-announces-positive-phase-2b-trial-results-of-rad-101-for-diagnosis-of-brain-metastases.html
Radiopharm Theranostics Ltd ADR RADX
July 16, 2026  |  morningstar.comM
Radiopharm Theranostics Limited Sponsored ADR
May 14, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/RADX
RADX: Fiscal 3Q:26 Cash Flow Report
May 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/radx-fiscal-3q-26-cash-092400408.html
Radiopharm Theranostics Ltd. ADR
May 13, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/radx/financials
Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs
April 28, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/radiopharm-theranostics-adr-radx-inside-the-clinical-programs-1748993/
Radiopharm Theranostics Reports Business Update
April 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/23/3279721/0/en/radiopharm-theranostics-reports-business-update.html
Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer ...
April 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/radiopharm-theranostics-presents-initial-findings-110000207.html
Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
April 16, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/radiopharm-theranostics-completes-enrollment-in-u-s-phase-2b-imaging-trial-of-rad-101-for-diagnosis-of-brain-metastases-1036028670
Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target increased by 752.98% to 39.26
April 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/radiopharm-theranostics-limited-depositary-receipt-radx-price-target-increased-by-752-98-to-39-26/ar-AA20YjrZ
Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target decreased by 11.04% to 4.60
April 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/radiopharm-theranostics-limited-depositary-receipt-radx-price-target-decreased-by-1104-to-460/ar-AA20utAZ
Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
April 8, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/radiopharm-theranostics-advances-to-cohort-3-in-177lu-rad202-phase-1-dose-escalating-clinical-trial-1036002743
Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
April 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/07/3268954/0/en/radiopharm-theranostics-and-siemens-healthineers-sign-clinical-supply-agreement-for-rad101-in-the-u-s.html
RADX: RAD 101 Phase IIb Interim Analysis
April 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/radx-rad-101-phase-iib-110400813.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dyadic International stock logo

Dyadic International NASDAQ:DYAI

$1.05 +0.05 (+5.51%)
Closing price 04:00 PM Eastern
Extended Trading
$0.99 -0.06 (-5.71%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Sensei Biotherapeutics stock logo

Sensei Biotherapeutics NASDAQ:FTH

$30.00 +1.43 (+5.01%)
Closing price 04:00 PM Eastern
Extended Trading
$29.02 -0.98 (-3.25%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Immuron stock logo

Immuron NASDAQ:IMRN

$1.10 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.10 -0.01 (-0.45%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

Radiopharm Theranostics stock logo

Radiopharm Theranostics NASDAQ:RADX

$2.86 +0.06 (+2.14%)
Closing price 04:00 PM Eastern
Extended Trading
$2.86 +0.01 (+0.17%)
As of 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas